Cloretazine for the treatment of acute myeloid leukemia

Expert Review of Anticancer Therapy
Norbert Vey, Frank Giles

Abstract

Cloretazine is a new sulfonylhydrazine alkylating agent with antileukemic activity. Phase I studies have shown myelosuppression to be the dose limiting toxicity in both solid tumors and leukemias. A large Phase II study of single agent cloretazine (600 mg/m2) confirmed its activity in patients with relapsed acute myeloid leukemia, and in elderly patients with previously untreated acute myeloid leukemia or myelodysplastic syndrome. It also confirmed the limited nonhematological toxicity, even in elderly patients. Cloretazine can be safely combined with cytarabine, and this combination regimen is currently being tested in a large Phase III study in patients with relapsed acute myeloid leukemia. Cloretazine is a promising new antileukemic agent that may be incorporated into an intensive combination regimen.

References

Aug 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M J KeatingE J Freireich
Nov 1, 1985·Revue française de transfusion et immuno-hématologie·B MascretY Carcassonne
Oct 1, 1980·The American Journal of Medicine·E Frei, G P Canellos
Apr 1, 1995·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S D'AtriG Papa
Jan 25, 1997·Lancet·A K Burnett, O B Eden
Nov 5, 1998·The New England Journal of Medicine·S L SoignetR P Warrell
Feb 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F J GilesH M Kantarjian
Aug 14, 2001·Critical Reviews in Oncology/hematology·A PintoF Ferrara
Jan 16, 2002·Current Opinion in Genetics & Development·Charles L Sawyers
May 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stanton L Gerson
Aug 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Karen SeiterTauseef Ahmed
Mar 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hagop M KantarjianMichael Keating
Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards
May 8, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Francis GilesHagop Kantarjian
Jun 11, 2004·Seminars in Hematology·Martin S Tallman
Jul 9, 2004·Cancer·Norbert VeyDominique Maraninchi
Nov 25, 2004·Hematology·Richard M StoneMikkael A Sekeres
Sep 15, 2005·British Journal of Haematology·Dimitri A Breems, Bob Löwenberg

❮ Previous
Next ❯

Citations

Mar 7, 2007·Expert Review of Anticancer Therapy·Gail J Roboz
Dec 9, 2015·European Journal of Operational Research·Yuncheol KangVittaldas V Prabhu
Dec 23, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gary J SchillerFrancis J Giles
Dec 6, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Francis GilesSusan O'Brien

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.